Two immune tolerance registries – the International Immune Tolerance Study Group (ITSG) and North American Immune Tolerance Study (NAITS) – are compared and findings from combined data reported. The registries differed with respect to data collection tools, location, host and environmental factors, start date distribution and treatment products. The success and failure rates were similar in the two studies. There was a highly significant association between maximum historical titre and immune tolerance success; the success rate decreased as the historical titre increased. There was a significant association between inhibitor titre immediately prior to treatment and the probability for treatment success, and between outcome and time from diagnosis to treatment in the ITSG (of borderline significance in the NAITS). There was a significant association between outcome and dose, though the direction of the associations was not the same. In the ITSG, success was associated with doses greater than or equal to 200 IU/kg/day, while in the NAITS, greater success was observed with doses of less than 50 IU/kg/day. There was no association between outcome and treatment product. Data from the two registries were combined to produce a table for calculating the chance of successful treatment by historical titre, pretreatment titre, and dose.

中文翻译：

---

国际免疫耐受登记处与北美免疫耐受登记处的比较


对两个免疫耐受登记机构——国际免疫耐受研究组 (ITSG) 和北美免疫耐受研究 (NAITS)——进行比较，并报告综合数据的结果。这些登记在数据收集工具、位置、宿主和环境因素、开始日期分布和治疗产品方面有所不同。这两项研究的成功率和失败率相似。最大历史滴度与免疫耐受成功率之间存在高度显着的关联；随着历史滴度的增加，成功率下降。在 ITSG 中，治疗前抑制剂滴度与治疗成功的可能性之间，以及结果与从诊断到治疗的时间之间存在显着相关性（在 NAITS 中具有临界意义）。结果和剂量之间存在显着关联，尽管关联的方向并不相同。在 ITSG 中，成功与大于或等于 200 IU/kg/天的剂量相关，而在 NAITS 中，观察到剂量低于 50 IU/kg/天的成功率更高。结果和治疗产品之间没有关联。将两个登记处的数据合并起来生成一个表格，用于根据历史滴度、治疗前滴度和剂量计算成功治疗的机会。